NADH

People discuss NADH for fatigue and brain fog, with reports ranging from clearer thinking to no change, worse fatigue or feeling too wired. It is the reduced form of a cellular coenzyme, distinct from NAD+, NMN and NR; the experiences below mainly concern oral or sublingual supplements, often alongside CoQ10.

What NADH is

• NADH means reduced nicotinamide adenine dinucleotide. It is a coenzyme involved in cellular energy chemistry: the reduced partner of NAD+. That biological role explains the interest, but does not show that swallowing more corrects the cause of fatigue. Official context Official context
• Similar names can hide different products. NADH, direct NAD+, NMN and NR are separate identities. ENADA appears in NADH reports; a commenter calling Niagen “NAD+” is describing an NR product, so that comparison cannot establish how direct NAD+ compares with NADH. Community Official context Official context
• Oral experience does not establish an injectable blend effect. The reports here concern tablets, chewables, sublingual products or unspecified supplement routes. They do not establish the response, ingredient contribution or dose of a supplier blend that includes NADH. Community

What people hope to feel

• Clearer thinking is one reported benefit. A sublingual user described less brain fog, while another NADH user reported no benefit. These accounts do not identify who is likely to respond. Community
• Fatigue improvements can be modest and hard to attribute. One person noticed only a small improvement after about a month with NADH and CoQ10. In an older account, feeling better coincided with B12 injections and greater attention to pacing. Community Community

Doses people discuss

• 10 mg is reported with both slight benefit and excessive intensity. In the 2022 thread, one ENADA user was unsure it helped; another found 10 mg at once too intense and described dividing it between morning and afternoon. The latter had recently added CoQ10; this is a report, not a tablet-splitting recommendation. Community
• 20 mg sublingual daily appears in a brain-fog account. A Phoenix Rising user reported greater alertness at that amount. This does not make 20 mg a typical or established effective dose. Community
• 20 mg NADH plus 200 mg CoQ10 is also a study-derived claim. A 2023 poster repeated those separate ingredient amounts from a paper, while actually reporting 10 mg NADH after starting 100 mg CoQ10. The quoted combination is not that person’s completed experience. Community
• Higher reports are isolated, with different forms and schedules. One reply described 50 mg NADH with 100 mg CoQ10 per chewable dose without a frequency; another reported 60 mg NADH daily for years without specifying route. Neither establishes a usual range or safety ceiling. Community

Half-life

• No credible numeric bodily half-life emerged from these reports. Feeling an effect quickly, missing a dose or noticing next-day fatigue cannot measure how fast NADH is cleared. There is no supported number here for planning repeat use. Community

Onset: when people notice something

• Immediate change and first-day nonresponse both appear. One ENADA user described an immediate effect after recently starting CoQ10; the 2023 poster noticed little on the first NADH day. Neither supplies a predictable waiting period. Community Community
• A small change after about a month is a combination report. The NADH-and-CoQ10 account cannot establish NADH’s onset alone. A separate forum claim that benefit takes about three months was a user’s retelling of clinician advice, alongside their own lack of benefit. Community Community

Duration: how long changes last

• Single-dose duration remains unclear. A chewable-combination user noticed feeling worse after a missed dose, but gave no elapsed hours. That does not distinguish NADH from CoQ10 or establish withdrawal. Community
• An early benefit can disappear during continued use. Mary recalled roughly ten days of improvement before it stopped helping, with later retries unsuccessful. This describes a course of experience, not a ten-day drug half-life. Community

Cycles and time off

• Daily use and widely spaced use are both described. Alongside daily reports, one user described one-quarter of a 5 mg tablet about every third day: nominally 1.25 mg per use, not 1.25 mg daily. Actual fragment content was not measured. Community
• Breaks are experiments, not a demonstrated reset. One poster planned a few weeks off after benefit faded; another had failed retries. Misfit Toy described years of earlier benefit but a later restart that caused insomnia, so previous tolerance did not predict the later experience. Community Community

What can feel wrong

• Worse fatigue is part of the record. The seed poster felt more tired and less mentally clear the day after 20 mg. The route was not stated, and the timing alone cannot establish causation. Community
• Even a small labeled amount can feel overstimulating. A 5 mg report included insomnia, dizziness, shakiness and a faster heart rate, with recent illness, other B vitamins and medications complicating the picture. Forum explanations about neurotransmitters or vasodilation remain speculation. Community
• Headache and stomach problems have uncertain causes. One sublingual user reported no effect at 25 mg and a severe headache at 50 mg after changing products. Another person stopped multiple supplements because of stomach trouble and could not tell whether NADH contributed. Community Community
• Feeling more awake is not proof of broader recovery. Several-month nonresponse and possible palpitations appear beside energy reports. The inspected accounts do not establish long-term safety, interactions or an ability to increase activity without consequences. Community Community

From community discussion

• CoQ10 makes the comparison especially easy to misread. In the same thread as a modest combination benefit, a reply praised CoQ10 while explicitly saying NADH had not yet been added. That reply is not independent support for the combination; other users reported no help from either. Community
• Trying it longer did not always reveal a benefit. SpecialK82 stopped after a couple of months without improvement and with possible heart-rate trouble; they also had pre-existing palpitations. GoddessinRepose reported several months without noticing a difference, despite the hopeful energy explanation. Community

What the human studies add

• A small early trial reported a signal worth investigating. Forsyth’s 1999 crossover pilot included 26 people with CFS and four-week periods of oral 10 mg NADH or placebo, separated by a four-week washout. Favorable responses were reported in 8 of 26 NADH periods versus 2 of 26 placebo periods; this small study does not establish a reliable benefit for an individual. Official context
• A later trial did not improve overall functioning. Alegre’s 2010 trial enrolled 86 people, with 77 completing follow-up, and compared oral 20 mg NADH with placebo during the first two months. Its abstract reports some anxiety and exercise heart-rate changes but no improvement in most clinical measures or global functional performance; these findings qualify the energy narrative. Official context